Figures & data
Figure 1. Patient disposition.
Table 1. Demographic and baseline characteristics.
Table 2. Patient incidence of postbaseline allo-HSCT.
Figure 2. Outcomes by line of salvage. (A) Overall survival. (B) Event-free survival (patients without remission were assigned an event-free survival of one day). (C) Duration of remission (includes only patients who achieved remission). (D) Overall survival by MRD response and by line of salvage in the blinatumomab group, in a landmark analysis starting at day 82. CI: confidence interval; HR: hazard ratio; K–M: Kaplan–Meier; MRD–: MRD response; MRD+: MRD non-response; NE: not estimable; NR: not reached; S1: first salvage; S2+: second or later salvage; +, censored patients.
Table 3. Best hematologic response and minimal residual disease response within 12 weeks of treatment initiation.
Table 4. Treatment emergent adverse events.